As the antibody–drug conjugate (ADC) landscape rapidly evolves, the industry is moving beyond traditional cytotoxic payloads and antibody-first development strategies toward more integrated, precision-engineered therapeutics. In a BioPharma Boa... Read more
In this BioPharma Boardroom interview, Steven Quay, Founder and CEO of Atossa Therapeutics, outlines the scientific rationale behind developing (Z)-endoxifen as a direct therapeutic rather than relying on the metabolic activation of Tamoxifen. He exp... Read more
As artificial intelligence becomes increasingly embedded in formulation science and early clinical planning, the industry faces a dual challenge: accelerating timelines while safeguarding scientific rigor, patient safety, and regulatory trust. In thi... Read more
Under the leadership of Joel Latham, Incannex Healthcare is advancing a differentiated pipeline of cannabinoid- and psychedelic-based therapeutics targeting significant unmet needs in sleep disorders, inflammatory disease, and anxiety... Read more
Highly potent drugs now account for over 30% of the global pipeline, with more than 1,000 molecules in development — Axplora’s investments in HPAPI capacity help customers bring these complex therapies to market faster $60 ... Read more
Expands Agilent’s pathology portfolio through addition of highly complementary antibody, reagent and instrument business with annual double-digit revenue and profit growth since 2021 Expected to be accretive to Agilent’s top-line gro... Read more
— $9M Second Phase of CDMO Investment Builds on 2025 $6M Expansion, Funding Facility Upgrades and Increased Capacity for Suppository, Semi-Solid, and Oral Solid Dose Capacity — — Enhancements Strengthen Domestic Supply Chains f... Read more
Neuland Laboratories will open its new commercial peptide facility in the summer of 2026 at its 17-acre Bonthapally manufacturing campus, with further capacity expansions planned as client demand increases. The first of four planned ... Read more
© 2026 Biopharma Boardroom. All Rights Reserved.
